国际妇产科学杂志
國際婦產科學雜誌
국제부산과학잡지
Journal Of International Obstetrics And Gynecology
2015年
5期
591-593
,共3页
卵巢肿瘤%CA-125抗原%CA-19-9抗原%CA-15-3抗原%癌胚抗原%诊断
卵巢腫瘤%CA-125抗原%CA-19-9抗原%CA-15-3抗原%癌胚抗原%診斷
란소종류%CA-125항원%CA-19-9항원%CA-15-3항원%암배항원%진단
Ovarian neoplasms%CA-125 antigen%CA-19-9 antigen%CA-15-3 antigen%Carcinoembryonic antigen%Diagnosis
目的：探讨血清糖类抗原125（CA125）及CA125联合CA199、CA153、癌胚抗原（CEA）检测在卵巢癌诊断中的意义。方法：采用化学发光微粒子免疫检测法测定71例卵巢癌患者、10例卵巢交界性肿瘤患者和42例卵巢良性肿瘤患者血清中CA125、CA199、CA153和CEA的含量，阳性诊断标准分别为：CA125＞35 kU/L，CA199＞37 kU/L， CA153＞30 kU/L，CEA＞5μg/L。结果：在单项肿瘤标记物中，CA125的阳性率最高（84.5%），敏感度、特异度和准确度指标平稳。在不同的联合检测方案中CA199、CA153与CA125联合检测方案最优，较CA125单项检测敏感度和准确度均有提高。晚期卵巢癌（Ⅲ～Ⅳ期）患者的CA153、CA125含量高于早期卵巢癌（Ⅰ～Ⅱ期）患者（P＜0.001）。结论：CA199、CA153、CEA与CA125在卵巢癌鉴别诊断中均有一定价值，并可以根据CA153、CA125含量判断患者卵巢癌的分期， CA199、CA153与CA125联合检测是诊断卵巢癌较为理想的标记物组合。
目的：探討血清糖類抗原125（CA125）及CA125聯閤CA199、CA153、癌胚抗原（CEA）檢測在卵巢癌診斷中的意義。方法：採用化學髮光微粒子免疫檢測法測定71例卵巢癌患者、10例卵巢交界性腫瘤患者和42例卵巢良性腫瘤患者血清中CA125、CA199、CA153和CEA的含量，暘性診斷標準分彆為：CA125＞35 kU/L，CA199＞37 kU/L， CA153＞30 kU/L，CEA＞5μg/L。結果：在單項腫瘤標記物中，CA125的暘性率最高（84.5%），敏感度、特異度和準確度指標平穩。在不同的聯閤檢測方案中CA199、CA153與CA125聯閤檢測方案最優，較CA125單項檢測敏感度和準確度均有提高。晚期卵巢癌（Ⅲ～Ⅳ期）患者的CA153、CA125含量高于早期卵巢癌（Ⅰ～Ⅱ期）患者（P＜0.001）。結論：CA199、CA153、CEA與CA125在卵巢癌鑒彆診斷中均有一定價值，併可以根據CA153、CA125含量判斷患者卵巢癌的分期， CA199、CA153與CA125聯閤檢測是診斷卵巢癌較為理想的標記物組閤。
목적：탐토혈청당류항원125（CA125）급CA125연합CA199、CA153、암배항원（CEA）검측재란소암진단중적의의。방법：채용화학발광미입자면역검측법측정71례란소암환자、10례란소교계성종류환자화42례란소량성종류환자혈청중CA125、CA199、CA153화CEA적함량，양성진단표준분별위：CA125＞35 kU/L，CA199＞37 kU/L， CA153＞30 kU/L，CEA＞5μg/L。결과：재단항종류표기물중，CA125적양성솔최고（84.5%），민감도、특이도화준학도지표평은。재불동적연합검측방안중CA199、CA153여CA125연합검측방안최우，교CA125단항검측민감도화준학도균유제고。만기란소암（Ⅲ～Ⅳ기）환자적CA153、CA125함량고우조기란소암（Ⅰ～Ⅱ기）환자（P＜0.001）。결론：CA199、CA153、CEA여CA125재란소암감별진단중균유일정개치，병가이근거CA153、CA125함량판단환자란소암적분기， CA199、CA153여CA125연합검측시진단란소암교위이상적표기물조합。
Objective:To evaluate the clinical value of serum CA125 and CA125 combined with CA199, CA153, CEA detections in the diagnosis of ovarian cancer. Methods: Chemiluminescent microparticle immunoassay was used to detect the serum levels of CA125, CA199, CA153 and CEA in 71 patients with ovarian cancer, 10 patients with borderline ovarian tumors and 42 patients with benign ovarian tumors. Positive diagnostic criteria of the four tumor marker:CA199>37 kU/L, CA153>30 kU/L, CEA>5μg/L, CA125>35 kU/L. Results:The positive rate (84.5%) of CA125 was highest among that of four tumor markers. The sensitivity, specificity and accuracy of CA125 were smooth. The combined detection of CA199, CA153, CA125 was optimal in the four different combinations. Compared with CA125 alone, the sensitivity and accuracy of combined detection of CA199, CA153, CA125 were significantly increased. The levels of CA153 and CA125 for ovarian cancer patients in stage Ⅲ-Ⅳwere obviously higher than those in stageⅠ-Ⅱ(P<0.001). Conclusions:CA199, CA153, CEA and CA125 have some value in the differential diagnosis of ovarian cancer. And we can determine the stage of ovarian cancer patients according to CA153, CA125 content. The combined detection of CA199, CA153 and CA125 is an ideal marker on diagnosis of ovarian cancer.
